Weight-loss drug developer Metsera raises $275 million in US IPO (updated)

MBX Biosciences

31/01/2025 24:49

(Adds details and background from paragraph 2 onwards)
       Jan 30 (Reuters) - Weight-loss drug developer Metsera
has raised $275 million after pricing its U.S. initial public
offering at $18 per share, above its targeted range, the ARCH
Venture Partners-backed biotech company said on Thursday.
    Investor sentiment improved on expectations of lower
corporate taxes and a more business-friendly regulatory
environment under the Donald Trump administration, leading to a
rejuvenation of the U.S. IPO market.
    New York City-based Metsera priced its offering of 17.19
million shares at $18 apiece. The company had marketed to list
its shares in a range of $15 to $17 each.
    The IPO valued the drug developer at $1.8 billion, ahead of
its Nasdaq market debut.
    The global weight-loss drug market, expected to be worth
about $150 billion by the early 2030s, has drawn increased
investor interest in companies targeting the fast-growing
segment.
        

 (Reporting by Prakhar Srivastava and Kanjyik Ghosh in
Bengaluru; Editing by Alan Barona)
 ((Prakhar.srivastava2@thomsonreuters.com))